A special video supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Dr Richard M Stone.
Design and results of the QUAZAR AML-001 maintenance trial assessing CC-486 versus placebo for patients with AML in first remission (00:00)
Mechanism of action of azacitidine in AML (04:09)
Preclinical data on the use of anti-inflammatory agents for clonal hematopoiesis of indeterminate potential (CHIP) (05:56)
Ongoing investigations of anti-CD47 antibodies, antibody-drug conjugates and immune checkpoint inhibitors for AML (07:40)
Clinical relevance of CHIP mutations (11:05)
Pathophysiology of CHIP mutations and cardiovascular disease (16:23)
Composition of CPX-351; advantages and disadvantages in the management of AML (17:45)
Efficacy and safety of CPX-351 for secondary AML; patient selection for treatment with CPX-351 (20:10)
Investigation of venetoclax-based combination strategies in AML (23:27)
Factors determining eligibility for intensive chemotherapy for older and younger patients with AML (26:10)
Counseling patients on potential outcomes of intensive chemotherapy for AML (30:51)
Duration of therapy with an HMA and venetoclax for patients with AML (34:27)
Genetic alterations in AML; incidence and biology of FLT3 mutations (36:12)
Clinical presentation of patients with AML with FLT3 mutations; activity of the FLT3 inhibitors gilteritinib and midostaurin (38:44)
Role of FLT3 inhibitors as a bridge to transplant and in the post-transplant setting (42:12)
Tolerability of FLT3 inhibitors for patients with AML and choice of agent in the post-transplant maintenance setting (45:18)
Evidence with and ongoing investigation of the FLT3 inhibitor quizartinib in patients with AML with a FLT3 mutation (47:28)
Incidence of IDH mutations in AML; treatment for AML with IDH1 and IDH2 mutations (49:45)
Differentiation syndrome with IDH inhibitors: Incidence, presentation and management (54:20)
Treatment options for patients with AML harboring IDH or FLT3 mutations who are unfit for intensive chemotherapy (57:02)
Future developments in the management of AML (59:28)
Long-term outcomes with HMA and venetoclax in AML (1:01:32)
Podden och tillhörande omslagsbild på den här sidan tillhör Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av, eller tillsammans med, Poddtoppen.
